Phase 2 Clinical Study Results in Treatment of Common Warts Selected for Oral Presentations
The details of the e-posters with oral presentations are as follows:
- Long-Term Efficacy and Safety of Hydrogen Peroxide Topical Solution, 45% (w/w) in Patients with Common Warts: Posttreatment Results from the Phase 2 WART-203 Trial
- Poster 10224
- Date and time of oral presentation:
Saturday, March 2, 10:25 a.m. to 10:30 a.m.
- Location of oral presentation: Hall H, ePoster Presentation Center 2
- Efficacy and Safety of Hydrogen Peroxide Topical Solution, 45% (w/w) for Treatment of Common Warts: 8-Week Results from the Phase 2 WART-203 Trial
- Poster 10150
- Date and time of oral presentation:
Sunday, March 3, 10:20 a.m. to 10:25 a.m.
- Location of oral presentation: Hall H, ePoster Presentation Center 1
In addition, the following original abstracts were accepted for e-poster presentation during the meeting:
- Poster 10235 - Rater Reliability Testing of the Physician Wart Assessment for Common Warts: A Noninterventional, Observational Study
- Poster 10497 - Effectiveness of Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities, and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study
- Poster 10513 - Safety of Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities, and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study
- Poster 10527 - Onset of Treatment Effectiveness with Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study
About A-101 45% Topical Solution
A-101 45% topical solution, an investigational medicine for the treatment of common warts, is a proprietary, stabilized, high concentration hydrogen peroxide topical solution, 45% (w/w), also referred to as HP45. It is being developed as a topical, non-invasive treatment for self-administration or administration by a caregiver. If approved, A-101 45% topical solution would be the first prescription medicine approved by the
About Common Warts
Common warts, also called verruca vulgaris, are skin growths caused by a virus infecting the top layer of the skin. They affect an estimated 22 million Americans each year with a higher incidence in children than adults. Common warts are often skin-colored and feel rough but can be darker and smooth. Symptoms include pain, bleeding, itching, and burning. Common warts are contagious and may interfere with social activities, cause embarrassment, and carry a social stigma. Each year, over 2 million people in the U.S. are diagnosed with common warts during a visit to a health care professional.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris’ clinical development of its investigational medicine, A-101 45% topical solution. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K filed for the year ended
Aclaris Therapeutics Contacts
Senior Vice President
Corporate Strategy/Investor Relations
Vice President, Corporate Communications
Source: Aclaris Therapeutics, Inc.